Format

Send to

Choose Destination
Anticancer Res. 2017 Jul;37(7):3947-3954.

Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study.

Author information

1
Seta Clinic Group, Tokyo, Japan takimoto@j-immunother.com.
2
Seta Clinic Group, Tokyo, Japan.

Abstract

BACKGROUND:

Conventional therapy for advanced gastric cancer (GC) has limited survival benefits. In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy, using in vitro-activated T-lymphocytes with and without dendritic cells (DCs), in combination with standard therapies in terms of the survival of patients with advanced GC.

PATIENTS AND METHODS:

A total of 242 patients who were diagnosed as having stage-IV GC were enrolled in this study to receive immune-cell therapy with or without standard therapies, such as chemotherapy, surgery, or radiation therapy. Overall survival was analyzed by the Kaplan-Meier with log-rank test and Cox regression methods.

RESULTS:

Immune-cell therapy increased median survival time (21.5 months) in patients with advanced GC. The patients who underwent surgery with or without chemotherapy as a prior treatment showed better prognosis than those who received other therapies (p<0.001). Patients who showed stable disease or a partial response to immune-cell therapy had a better prognosis than those with progressive disease (p<0.001). Multivariate analysis revealed that performance status, the type of immune-cell therapy, and prior treatment were independent prognostic factors for patients with GC. No serious adverse event was reported in immune-cell therapy.

CONCLUSION:

Immune-cell therapy might extend the survival of patients with advanced GC.

KEYWORDS:

Immune-cell therapy; chemotherapy; gastric cancer; surgical operation

PMID:
28668899
DOI:
10.21873/anticanres.11778
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center